efgartigimod + prednisone

Efgartigimod + prednisone is a **combination therapy** consisting of **efgartigimod** (a neonatal Fc receptor [FcRn] antagonist, typically administered as efgartigimod alfa) and **prednisone** (a systemic corticosteroid). Efgartigimod is a human IgG1-derived Fc fragment that blocks the FcRn receptor, reducing the circulating levels of pathogenic IgG autoantibodies. Prednisone is a glucocorticoid with broad immunosuppressive and anti-inflammatory actions. This combination is being investigated and sometimes used for the treatment of IgG-mediated autoimmune diseases, aiming for more rapid disease control and reduction in corticosteroid requirements. The combination has been explored in diseases such as **pemphigus vulgaris**, **pemphigus foliaceus**, **immune-mediated necrotizing myopathy (IMNM)**, and **myasthenia gravis**, generally as efgartigimod add-on to corticosteroid regimens. The synergy leverages fast IgG reduction by efgartigimod and the anti-inflammatory action of prednisone, with the goal of faster remission and fewer adverse effects from prolonged steroid therapy[1][2][3][6].